Profound Medical Corp (PROF) Stock Forecast & Price Target
Profound Medical Corp · NASDAQ
$5.98+0.02 (+0.34%)
15-min delayed · Sep 11, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Profound Medical Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 101% above the current $5.98. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Profound Medical Corp.
As of Sep, 1 of 1 firms rate PROF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PROF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.19 – $-0.18 · 4 analysts · -31% YoY
Next period, 4 analysts expect Profound Medical Corp to earn $-0.18 a share (range $-0.19 – $-0.18), versus $-0.27 a year earlier. Full-year consensus is $-0.86, growing to $-0.59 the year after.
REVENUE · NEXT QUARTER
$13.9M
Range $12.5M – $15.5M · 4 analysts · +69% YoY
Revenue is expected to reach $13.9M (range $12.5M – $15.5M), +69.1% year-over-year. Full-year consensus is $36.2M, rising to $59.5M next year.
Top analysts covering Profound Medical Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PROF.
#1
BH
Benjamin Haynor
Lake Street
Buy
$12.00+100.7% to target
Coverage
—
+ Follow
#2
MF
Michael Freeman
Raymond James
Buy
$11.00+83.9% to target
Coverage
—
+ Follow
PROF stock forecast FAQ
What is PROF's average 12-month price target?+
The 1 analysts with a live target average $12.00 for Profound Medical Corp over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is PROF stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PROF?+
1 analysts have an active rating on Profound Medical Corp, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PROF?+
Among analysts who currently cover PROF, Benjamin Haynor of Lake Street has the strongest overall Quantellect track record. Their current call is Buy with a $12.00 target.
What is Profound Medical Corp's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.19 – $-0.18) across 4 analysts. Full-year EPS is projected at $-0.86, rising to $-0.59 the following year.
How much revenue is Profound Medical Corp expected to report next quarter?+
Consensus revenue is $13.9M (range $12.5M – $15.5M). Full-year revenue is projected at $36.2M, growing to $59.5M next year.
Have analysts been upgrading or downgrading PROF lately?+
As of Sep, 1 of 1 firms rate PROF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PROF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
